Both Fostair 200/6 and Fostair NEXThaler 200/6 are licensed for the treatment of asthma where use of a combination product comprising a long-acting ß2-agonist and an inhaled corticosteroid is appropriate. Two inhalations are given twice daily.
Another recent change to the Fostair range was the addition of severe COPD to the licensed indications for Fostair NEXThaler 100/6. Both the Fostair 100/6 metered-dose inhaler and the Fostair NEXThaler 100/6 dry powder inhaler are now licensed for the symptomatic treatment of severe COPD and for the treatment of asthma.
Prescribers should note that the beclometasone doses in Fostair products are not equivalent to those delivered by non-extrafine formulations. Owing to the difference in particle sizes, 250 microgram beclometasone administered via a standard inhaler is therapeutically equivalent to 100 microgram beclometasone in a Fostair product when given via the NEXThaler device or the Fostair metered dose inhaler.